Cell therapy is one of the most promising advances in modern cancer treatment. The basic concept involves collecting a patient’s own immune cells, genetically reprogramming them in the laboratory so they recognize cancer more effectively, and then infusing them back into the patient’s body. Once circulating, these enhanced immune cells are designed to seek out and destroy cancer cells while leaving healthy tissue largely untouched. The approach has already produced remarkable results in certain blood cancers, where engineered CAR T-cell therapies have driven durable remissions in patients who had exhausted conventional options. Translating that success to solid tumors, however, has proven far more difficult. Solid tumors build defensive microenvironments that suppress immune activity, physically exclude T cells and exhaust the cells that do manage to infiltrate. The new UChicago Medicine trial is designed specifically to confront those barriers, combining tumor recognition with engineered resistance to the immunosuppressive signals that tumors deploy.

The scientific foundation of the treatment differs in an important way from existing CAR T-cell platforms. Conventional CAR T cells use engineered synthetic receptors that recognize proteins displayed on the surface of cancer cells. The UChicago team, by contrast, is using specially engineered T-cell receptors, the natural antigen-recognition machinery of the immune system, which allow immune cells to detect protein fragments presented from inside cancer cells. This distinction matters enormously for the range of cancers that can be targeted. Many of the most attractive tumor-associated proteins are not displayed on the cell surface but are processed internally and presented on major histocompatibility complex molecules, invisible to CAR constructs but perfectly visible to a properly directed T-cell receptor. By exploiting this intracellular surveillance pathway, the researchers dramatically expand the universe of tumors that engineered cell therapies might plausibly attack.

Richard Koya, MD, PhD, Professor of Obstetrics and Gynecology at UChicago Medicine, is the scientific investigator who developed the treatment and designed the clinical trial on the basis of many years of laboratory research. He framed the strategy as an extension of the immune system’s own logic. The team, he explained, is using the same natural process the immune system relies on to fight infections, but redirecting it to attack cancer. The stated goal is to create immune cells that can recognize cancer more effectively, survive longer and continue fighting the disease over time. That emphasis on persistence reflects a central lesson of immunotherapy research: engineered cells that fade quickly or become dysfunctional inside tumors rarely produce lasting benefit, whereas cells that endure and form immune memory may hold tumors in check long after the initial infusion.

The treatment protocol unfolds in several carefully sequenced stages. Doctors will first collect a patient’s white blood cells through a process similar to blood donation. Patients will then receive the chemotherapy drug decitabine, chosen for a specific biological effect: it increases the production of a cancer protein called NY-ESO-1, a target found in many tumors but absent from healthy adult tissues. This priming step is intended to make tumor cells more visible to the engineered immune cells that will follow. In the laboratory, researchers will then genetically engineer the patient’s immune cells with two critical features. The first is a T-cell receptor that recognizes NY-ESO-1, equipping the cells to identify and attack cancer. The second is a genetic modification that blocks TGF-beta, a signaling molecule that normally suppresses immune responses and contributes to T-cell exhaustion inside tumors, one of the principal reasons cell therapies have underperformed against solid disease.

Once the engineering is complete, the enhanced immune cells will be infused back into the patient through an intravenous line, much like a blood transfusion. Patients will also receive a low dose of interleukin-2, an immune-boosting drug that helps the engineered T cells multiply and remain active after they enter the body. The investigators plan to infuse approximately one billion engineered T cells into each patient, a dose intended to generate a powerful and durable immune response against cancers that currently have few effective treatment options. Researchers believe this combination, antigen targeting, resistance to suppressive signaling and cytokine support, could produce a stronger and longer-lasting immune response because it addresses one of the biggest challenges in solid tumor treatment: the hostile tumor environment that often weakens cancer-fighting immune cells before they can eliminate the tumor. By engineering T cells to resist signals such as TGF-beta, the team hopes the cells will persist longer, develop lasting immune memory and continue attacking tumors over time.

The trial’s design and execution are notable for their institutional provenance. This is an investigator-initiated clinical trial, meaning the treatment was conceived and developed by University of Chicago researchers rather than a commercial sponsor. The UChicago Medicine Comprehensive Cancer Center, which operates one of the nation’s largest cancer clinical trials programs, has extensive experience translating laboratory discoveries into early-stage clinical studies, and that infrastructure is now being applied to a therapy the institution controls end to end. Critically, the engineered cells will be produced in UChicago Medicine’s Good Manufacturing Practices facility, a highly specialized laboratory that meets strict federal standards for producing cell therapies. On-site manufacturing allows researchers to oversee every step of the process, maintain quality control and accelerate the translation of discoveries from the laboratory to patients, a capability that very few academic medical centers possess.

Koya emphasized the strategic value of that capability. Very few academic medical centers, he noted, have the ability to manufacture personalized cell therapies entirely on-site, and he described the arrangement as giving the team tremendous flexibility to rapidly test new ideas and move promising treatments to patients. That flexibility is particularly consequential in the fast-moving field of cellular immunotherapy, where iterative design changes, new receptor constructs and combination strategies often emerge faster than commercial pipelines can accommodate. An academic GMP facility effectively shortens the distance between a laboratory observation and a patient-ready product, allowing investigators to refine the therapy across successive cohorts in ways that industry-sponsored trials, bound by fixed manufacturing contracts and regulatory timelines, often cannot.

The Phase 1/2A trial will evaluate the experimental therapy in a small group of patients with metastatic ovarian cancer, soft tissue sarcoma, bladder cancer, prostate cancer, breast cancer, melanoma or non-small cell lung cancer, all cancers that form solid tumors and all diseases in which effective options narrow sharply once the disease has spread. Beginning in October 2026, screening for eligible patients will take place at UChicago Medicine locations in Hyde Park, New Lenox, Harvey, Flossmoor, Calumet City and Tinley Park in Illinois, and Crown Point in Indiana, with treatment taking place at the main campus in Hyde Park. UChicago Medicine oncologist Daniel Olson, MD, Assistant Professor of Medicine, is the clinical investigator overseeing the trial, while Thinle Chodon, MD, PhD, research professor, is overseeing production of the engineered cells in the institution’s GMP facility. The division of roles between clinical leadership and manufacturing oversight reflects the operational complexity of personalized cell therapy, in which each patient’s product is a bespoke biological medicine.

The launch arrives as UChicago Medicine continues to expand its cancer care and research enterprise. The institution was among the first medical centers in the country to offer FDA-approved CAR T-cell therapy for adults and children with certain blood cancers, and more recently became one of the first centers to provide tumor-infiltrating lymphocyte therapy for advanced melanoma, establishing a track record at the leading edge of cellular immunology. In April 2027, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion, Chicago’s first freestanding cancer pavilion, intended to bring advanced diagnostics, innovative treatments, translational discoveries and comprehensive support services to patients and the surrounding community. For patients with advanced solid tumors, the new trial offers something more immediate: a chance to access an immunotherapy approach that targets hidden tumor proteins, resists the suppressive forces of the tumor microenvironment and is produced by the same institution treating them, a model of academic self-reliance that may shape how the next generation of cancer cell therapies reaches the clinic.

Subject of Research: A Phase 1/2A clinical trial of an investigator-developed engineered T-cell receptor therapy targeting NY-ESO-1 for advanced solid tumors

Article Title: UChicago Medicine launches homegrown cell therapy for advanced solid tumors

Article References: UChicago Medicine launches homegrown cell therapy for advanced solid tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cell therapy, T-cell receptor, solid tumors, NY-ESO-1, TGF-beta, ovarian cancer, CAR T-cell therapy, GMP manufacturing, clinical trial, immunotherapy, decitabine, interleukin-2

The investigation began in the single-cell realm. Rather than grinding whole tumors into an averaged molecular signature, the researchers mined publicly available single-cell RNA sequencing data from 17 papillary thyroid carcinoma samples drawn from three independent public repositories. After rigorous quality control, they used a technique called Harmony to correct for the technical batch effects that arise when samples are processed in different laboratories, then annotated the tumor ecosystems cell by cell. This resolved the expected cast of characters: epithelial cells, fibroblasts, endothelial cells, pericytes, macrophages, T cells, NK cells, B cells, plasma cells, and rarer immune populations. The epithelial compartment, the seedbed of carcinoma itself, was then subdivided into ten subclusters for closer scrutiny.

Here the study deployed one of its most technically elegant moves: copy-number inference. Normal cells carry two copies of every chromosome, but cancer cells accumulate large-scale chromosomal gains and losses. Using the InferCNV pipeline, with macrophages serving as a genomically clean reference population, the team quantified these broad alterations in each individual epithelial cell. One subcluster, designated C6, showed copy-number disruption as severe as any malignant population, confirming its cancerous identity. Critically, this population also expressed high levels of CRABP1 while retaining classical epithelial markers such as CDH1, the gene encoding E-cadherin, and KRT19, a keratin characteristic of thyroid lining cells. In other words, CRABP1 did not mark an infiltrating stromal cell type; it marked a specific, bona fide malignant epithelial state.

Did that state matter clinically? To find out, the researchers turned to The Cancer Genome Atlas thyroid carcinoma cohort, the largest publicly available bulk transcriptomic dataset for the disease. Differential-expression analysis using DESeq2, with shrinkage of fold-change estimates to guard against noise, revealed that tumors with lymph-node metastasis expressed significantly less CRABP1 than node-negative tumors. CRABP1 levels also varied across pathological T categories, a measure of primary tumor size and local extent, and were lower in tumors than in adjacent healthy thyroid tissue. An exploratory gene set enrichment analysis in an external 157-patient cohort added texture: CRABP1-low tumors showed reduced enrichment for focal adhesion and tight junction pathways and elevated oxidative phosphorylation signatures. The authors are careful to frame these as unadjusted observational associations, but the direction is consistent and biologically coherent.

Correlation is cheap, so the team moved into the wet laboratory. Among seven thyroid cancer cell lines screened by quantitative PCR, HTC-C3, an anaplastic-derived line, expressed the most CRABP1, while FTC-238, isolated from a metastatic follicular carcinoma, expressed comparatively little. These became the complementary test beds. Silencing CRABP1 with small interfering RNAs in HTC-C3 cells made them visibly more mobile: in Transwell assays, cells must squeeze through 8-micrometer pores, and with a Matrigel coating mimicking basement membrane, they must also digest their way through. CRABP1-depleted cells crossed more of both barriers. Conversely, forcing CRABP1 overexpression in FTC-238 cells suppressed migration and invasion. The molecular fingerprint accompanied the behavior: CRABP1 knockdown lowered E-cadherin and raised N-cadherin, Vimentin, and Snail, a classic epithelial-mesenchymal transition signature, while overexpression reversed the pattern.

The in vivo evidence followed. The researchers injected control or CRABP1-depleted HTC-C3 cells into the flanks of immunodeficient BALB/c nude mice and tracked tumor growth for 24 days. Tumors lacking CRABP1 grew faster and ended heavier, and their tissue showed higher Ki-67 staining, a marker of cell proliferation, along with the same E-cadherin-low, mesenchymal-high gene expression shift seen in culture. CRABP1 depletion, in short, pushed thyroid cancer cells toward a more proliferative, more invasive, more mesenchymal identity inside a living animal, not just on plastic.

What silences CRABP1 in the first place? The team’s epigenetic analysis points toward DNA methylation, the chemical addition of methyl groups to cytosines that can dampen gene activity. Using the UALCAN portal on TCGA methylation arrays, they found that aggregated methylation of promoter-region probes near the CRABP1 transcription start site was higher in primary tumors than in normal thyroid, in both node-positive and node-negative disease. Probe-level mapping sharpened the picture: one CpG site, cg02276974, sits inside intron 2 of the CRABP1 gene on the south shore of a CpG island, and in 505 matched tumor samples its methylation was weakly but significantly inversely correlated with CRABP1 RNA abundance, with a Pearson correlation of minus 0.2069. The authors are explicit that this single site explains only about four percent of expression variation and cannot be declared a causal regulatory element, but it is a concrete, testable lead.

To probe that lead pharmacologically, they applied decitabine, a demethylating agent that inhibits DNA methyltransferases and is already approved in oncology for myelodysplastic syndromes. In both cell models, decitabine reduced migration, invasion, and Vimentin fluorescence intensity, and the strongest suppression appeared in CRABP1-overexpressing cells treated with the drug. In the xenograft setting, decitabine was associated with lower tumor weight and volume in the CRABP1-depleted background, alongside reduced Ki-67 and shifted EMT marker expression. Because decitabine acts genome-wide, these experiments establish a methylation-associated pharmacological context rather than proving that the drug specifically resurrects CRABP1 or unmethylates that particular intronic site. Notably, the animal design lacked a control-plus-decitabine arm, a limitation the authors candidly acknowledge.

The study also sketches the tumor’s social network. Using CellChat, a computational tool that predicts ligand-receptor crosstalk from transcriptomic data, the team found that CRABP1-positive malignant epithelial cells appeared poised to communicate with macrophage subpopulations through APP-CD74 and PPIA-BSG signaling axes. These predictions are hypotheses, not demonstrations of physical signaling, but they suggest that this malignant state may help sculpt its own inflammatory microenvironment, a question that now invites experimental testing with co-culture and spatial profiling approaches.

The implications ripple outward in several directions. Clinically, CRABP1 joins a growing list of markers that could eventually help separate tumors worth surgery from those suitable for active surveillance, an increasingly urgent distinction given evidence that a large fraction of diagnosed papillary thyroid carcinomas represent overdiagnosis. Scientifically, the work reframes a bulk-level gene finding as a single-cell state question, reminding researchers that a gene’s clinical signal may reflect the changing prevalence of a particular cell population within the tumor rather than uniform behavior across all cells. And pharmacologically, the decitabine results hint that demethylating therapy could blunt invasive phenotypes in methylation-driven contexts, though the bridge from nude mice to patients remains long and untested. The authors themselves draw careful boundaries: associations are associations, drug responses are drug responses, and no locus-specific epigenetic causality has been established. That restraint is precisely what makes the findings credible. What the study does deliver is a sharply defined malignant epithelial state, a plausible epigenetic handle on its regulation, and a concrete experimental agenda for turning CRABP1 from a molecular curiosity into a clinically useful signpost for thyroid cancer patients.

Subject of Research: CRABP1 downregulation and methylation in aggressive papillary thyroid carcinoma

Article Title: Methylation-associated downregulation of CRABP1 marks an aggressive malignant epithelial cell state in thyroid carcinoma

Article References: Fu, T., Li, Y., Huang, G., Hu, X., Luo, G., Wang, C., Wang, Y., Ding, Z., Zhou, J., & Li, Z. (2026). Methylation-associated downregulation of CRABP1 marks an aggressive malignant epithelial cell state in thyroid carcinoma. Frontiers in Cell and Developmental Biology, 14, Article 1974822. https://doi.org/10.3389/fcell.2026.1974822

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1974822

Keywords: CRABP1, papillary thyroid carcinoma, single-cell RNA sequencing, DNA methylation, decitabine, epithelial-mesenchymal transition, lymph node metastasis, copy number variation, TCGA, tumor microenvironment, retinoic acid signaling, cancer epigenetics

The case began deceptively. The patient, previously healthy, arrived at the hospital in November 2019 with a one-month history of cough. He had no exposure history to toxins, dust or radiation, no family history of haematological disease, and, strikingly, no physical signs that would raise immediate alarm: no enlarged spleen or liver, no swollen lymph nodes, no skin involvement, and none of the flushing, itching or other symptoms of hyperhistaminemia that often accompany basophil-driven leukaemias. Yet his blood counts told a grimmer story. He was profoundly pancytopenic, with a white cell count of just 2.41 × 10⁹ per litre, haemoglobin of 3.7 g/dL and platelets of 12 × 10⁹ per litre, and a differential count in which a remarkable 60 percent of his circulating white cells were basophils.

A bone marrow aspirate deepened the puzzle. The marrow was hypocellular, containing 25 percent blast cells alongside 28 percent immature basophils. The blasts were medium-sized, with immature nuclei and moderate cytoplasm studded with coarse basophilic granules; no Auer rods were seen, and there was no morphological evidence of dysplasia or haemophagocytosis. When stained with toluidine blue, the blasts and immature basophils displayed metachromasia, the colour-shift reaction that is the cytological hallmark of the basophil and mast cell lineages. Electron microscopy went further, confirming round cytoplasmic granules packed with finely particulate electron-dense material inside the leukaemic cells.

Immunophenotyping by flow cytometry revealed two distinct malignant populations. The blasts expressed the stem cell and myeloid markers CD34, CD33, CD13, CD45, HLA-DR and CD117, while the immature basophils carried the basophil-associated signature CD33, CD13, CD203c, CD123, CD9, CD22, CD15 and CD11b. Critically, neither population expressed myeloperoxidase, a cytochemical negativity that is central to distinguishing basophilic leukaemia from other myeloid proliferations and, in the 2022 WHO framework, from mast cell leukaemia. Serum tryptase and histamine were normal, arguing against a mast cell disorder and helping to lock in the diagnosis of acute basophilic leukaemia.

The genetics, however, shifted the classification decisively. Conventional cytogenetics uncovered a complex karyotype and monosomal karyotype, including a der(X;1)(p11;p22), monosomy 1, t(4;20)(q31;q11), a der(7;13)(p10;q10), trisomy 8, and multiple additional structural abnormalities. Reverse transcriptase PCR was positive for WT1 and PRAME and negative for PML-RARA, DEK-NUP214 and BCR-ABL1 fusions, excluding promyelocytic and chronic myeloid leukaemia-related entities. Next-generation sequencing of a 235-gene haematological malignancy panel identified a TP53 mutation (p.I255N) with a variant allele frequency of nearly 72 percent. Under the 2022 WHO classification, these MDS-defining cytogenetic abnormalities override morphological categories, meaning the patient’s disease was formally classified as AML-MR presenting with acute basophilic leukaemia, and placed firmly in the high-risk category.

AML-MR itself is a category that has evolved considerably since its introduction in the 2008 WHO classification. It defines a clonal myeloid neoplasm with 20 percent or more blasts carrying the cytogenetic or molecular abnormalities typically seen in myelodysplastic syndromes, whether arising de novo or after known MDS or MDS/MPN. Its prognosis is among the poorest in acute myeloid leukaemia, driven largely by age, antecedent disease and karyotype. Retrospective analyses have shown that patients with MDS-defining cytogenetic abnormalities have markedly shortened overall survival, with median survival of roughly 4 to 7 months when complex or monosomal karyotypes are present, and that multiple TP53 mutations predict even worse outcomes than a single mutant allele.

Acute basophilic leukaemia, meanwhile, accounts for less than 2 percent of all haematopoietic malignancies, and most reported cases have emerged as transformation from chronic myeloid leukaemia, myelodysplastic syndromes or myeloproliferative neoplasms rather than as a de novo diagnosis. Its reported survival ranges from 2 to 16 months, reflecting a rapid clinical course and frequent resistance to therapy. Diagnostic consensus requires metachromasia on toluidine blue staining, negativity for myeloperoxidase, Sudan black B and non-specific esterase, and the absence of strong CD117 expression to exclude mast cell leukaemia, all features satisfied in this case. No characteristic marker chromosome has been described for ABL, underscoring how much remains unknown about its biology.

Treatment presented a dilemma familiar to oncologists treating elderly, high-risk patients. Because of the patient’s high ECOG performance status concerns, the team chose decitabine combined with a lower-dose CAG regimen, cytarabine, aclarubicin and G-CSF priming, a hypomethylating agent-based strategy known as D-CAG. The disease responded completely. After four consolidation courses, the patient remained in remission for ten months, a notable achievement given his constellation of adverse factors. Intriguingly, when he relapsed in September 2020, the leukaemia had shed its basophilic identity: abundant blasts were present, but no basophils were detectable by morphology or flow cytometry, while the complex karyotype and the TP53 p.I255N mutation persisted at a slightly higher variant allele frequency. The authors suggest that the hypomethylating agent may have been responsible for the unusually durable first remission, noting literature indicating that epigenetic drugs such as hypomethylating agents and histone deacetylase inhibitors can be effective against TP53-mutated AML.

The relapse proved merciless. The patient’s disease resisted multiple successive therapies, including venetoclax, dasatinib, arsenite and homoharringtonine, and he died of sepsis in February 2021. Allogeneic haematopoietic stem cell transplantation, which offers a modest survival benefit in TP53-mutated complex-karyotype AML, was declined because of age and economic constraints. The case thus illustrates both the promise and the limits of current approaches: epigenetic combination therapy can buy meaningful time even in molecularly ominous disease, but relapsed TP53-mutant AML remains one of haemato-oncology’s most stubborn challenges.

The report arrives amid a wave of investigational strategies aimed squarely at TP53-mutant myeloid neoplasms. Eprenetapopt, a first-in-class reactivator of mutant p53, combined with azacitidine produced an overall response rate of 71 percent and a median overall survival of 10.8 months in TP53-mutant MDS and AML, while the anti-CD47 antibody magrolimab plus azacitidine achieved an overall response rate of 71 percent and a median overall survival of 12.9 months in an early-phase trial. Immune checkpoint inhibitors, CD123 × CD3 bispecific antibodies and CAR-T cell therapies are all under study, though none has yet delivered breakthrough efficacy in this genetically defined subgroup. For clinicians, the message of this singular case is twofold: basophilic differentiation can be the presenting face of AML-MR, and cytogenetics must trump morphology when the two diverge; and for the growing population of patients with TP53-mutated, complex-karyotype disease, the therapeutic frontier lies in targeted and immunological approaches that do not yet exist in standard practice. As the first documented instance of AML-MR presenting as acute basophilic leukaemia at diagnosis, the case adds a rare but instructive data point to the literature on two of the most feared entities in myeloid malignancy.

Subject of Research: A rare case of acute myeloid leukaemia-myelodysplasia related presenting as acute basophilic leukaemia at diagnosis.

Article Title: Acute myeloid leukaemia-myelodysplasia related (AML-MR) presented with acute basophilic leukaemia at diagnosis

Article References: Liu, J.-X., Wang, C.-J., & Zhang, M.-X. (2026). Acute myeloid leukaemia-myelodysplasia related (AML-MR) presented with acute basophilic leukaemia at diagnosis. Holistic Integrative Oncology, 5(1), Article 68. https://doi.org/10.1007/s44178-026-00291-8

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00291-8

Keywords: acute myeloid leukaemia, AML-MR, acute basophilic leukaemia, myelodysplasia, TP53 mutation, complex karyotype, decitabine, hypomethylating agents, WHO classification, flow cytometry, leukaemia relapse, targeted therapy